Immunophenotypical analysis and immunobiology of childhood brain tumors

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 2973-2992

  Bodey, Bela ^a,e   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e Unit 1   (United States)

Author keywords

Adoptive cellular immunotherapy; Angiogenesis related therapy; Apoptosis; Astrocytoma (ASTR); Immunocytochemistry; Immunophenotype (IP); Library on monoclonal antibodies (MoABs); Medulloblastoma (MED); Primitive neuroectodermal tumor (PNET); Tumor infiltrating leukocytes (TIL); Tumor related angiogenesis (TRA)

Indexed keywords

ALKALINE PHOSPHATASE; BIOTIN; CD8 ANTIGEN; CYTOKERATIN; ENDOGLIN; FAS ANTIGEN; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NEUROFILAMENT PROTEIN; PEROXIDASE; STREPTAVIDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; VIMENTIN;

ANTIGEN DETECTION; ANTIGEN PRESENTATION; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CHOROID PLEXUS PAPILLOMA; EFFECTOR CELL; GRANULOCYTE; HUMAN; HUMAN TISSUE; IMMUNOBIOLOGY; IMMUNOPHENOTYPING; INFLAMMATION; LYMPHOCYTE CLONE; MALIGNANT TRANSFORMATION; MEDULLOBLASTOMA; NERVE CELL DIFFERENTIATION; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROMYELOCYTE; SOLID TUMOR; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

BRAIN NEOPLASMS; CHILD; HUMANS; IMMUNOPHENOTYPING;

EID: 0033451098     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (174)

1. Virchow R: Cellular pathology. New York, RM de Witt, 1860.
2. Kun LE: Brain tumors: challenges and directions. Pediatr Clin North Am 44: 907-917, 1997.
3. Kedar A: Chemotherapy for pediatric brain tumors. Semin Pediatr Neurol 4: 320-332, 1997.
4. Becker LE, Hinton D: Primitive neuroectodermal tumors of the central nervous system. Human Pathol 14: 538-550, 1983.
5. Becker LE, Hinton D: Primitive neuroepithelial tumors of the central nervous system. In: Pathology of Neoplasia in Children and Adolescents (Feingold M, ed). Philadelphia, WB Saunders, 1986, pp 397-418.
6. van den Berg SR, Herman MM, Rubinstein LJ: Embryonal central neuroepithelial tumors: current concepts and future challenges. Cancer Metast Rev 5: 343-364, 1987.
7. Triche TJ: Primitive neuroectodermal tumors. Arch Pathol Lab Med 111: 311-312, 1987.
8. Packer RJ: Childhood tumors. Curr Opin Pediatr 9: 551-557, 1997.
9. Rickert CH, Probst-Cousin S, Gullotta F: Primary intracranial neoplasms of infancy and early childhood. Childs Nerv Syst 13: 507-513, 1997.
10. Pomeroy SL, Sutton ME, Goumnerova LC, Segal RA: Neurotrophins in cerebellar granule cell development and medulloblastoma. J Neurooncol 35: 347-352, 1997.
11. Nishio S, Morioka T, Takeshita I, Fukui M: Medulloblastoma: survival and late recurrence after the Collins' risk period. Neurosurg Rev 20: 245-249, 1997.
12. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST, Valentine MB, Behm FG, Li H, Heideman RL, Kun LE, Shapiro DN, Look AT: Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 57: 4042-4047, 1997.
13. Cairncross JG, Mattes MJ, Beresford HR, Albino AP, Houghton AN, Lloyd KO, Old LJ: Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci USA 79: 5641-5645, 1982.
14. Rettig WJ, Nishimura H, Yenamandra AK, Seki T, Obata F, Beresford HR, Old LJ, Silver J: Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids. J Immunol 138: 4484-4489, 1987.
15. Osborn M, Weber K: Immunofluorescence and immunocytochemical procedures with affinity purified antibodies: tubulin-containing structures. Methods Cell Biol 24: 97-132, 1982.
16. Perentes E, Rubinstein LJ: Recent applications of immunoperoxidase histochemistry in human neuro-oncology. Arch Pathol Lab Med 111: 796-812, 1987.
17. Grajkowska W, Cielecka-Kuszyk J, Jozwiak S, Roszkowski M, Drabik K: Immunohistochemical and ultrastructural studies of subependymal giant cell astrocytomas in children with tuberous sclerosis. Neurol Neurochir Pol 31: 509-521, 1997.
18. Palmer JO, Kasselberg AG, Netsky MG: Differentiation of medulloblastoma: studies including immunohistochemical localization of glial fibrillary acidic protein. J Neurosurg 55: 161-169, 1981.
19. Sharp G, Osborn M, Weber K: Occurrence of two different intermediate filament proteins in the same filament in situ within a human glioma cell line. An immunoelectron microscopical study. Exp Cell Res 141: 385-395, 1982.
20. Seeger RC, Danon YL, Rayner SA, Hoover F: Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol 128: 983-989, 1982.
21. Debus E, Weber K, Osborn M: Monoclonal antibodies specific for glial fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides. Differentiation 25: 193-203, 1983.
22. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983.
23. Nelson DF, Tsukada Y, Schoenfeld D, Fulling K, LaMarche J, Peress N: Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52: 550-554, 1983.
24. Giordana MT, Mauro A, Migheli A, Schiffer D: Contribution of immunohistochemistry to the problem of differentiation in medulloblastoma. Ital J Neurol Sci 4: 411-415, 1983.
25. Osborn M: Intermediate filaments as histologic markers: an overview. J Invest Dermatol 81 (Suppl. 1): 104S-109S, 1983.
26. Osborn M, Weber K: Intermediate filaments: cell-type specific markers in differentiation and pathology. Cell 31: 303-306, 1982.
27. Osborn M, Weber K: Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 48: 372-394, 1983.
28. Schindler E, Gullotta F: Glial fibrillary acidic protein in medulloblastomas and other embryonic CNS tumors of children. Virchows Arch (Pathol Anat) 398: 263-275, 1983.
29. Weber K, Shaw G, Osborn M, Debus E, Geisler N: Neurofilaments, a subclass of intermediate filaments: structure and expression. Cold Spring Harb Symp Quant Biol 48: 717-729, 1983.
30. Velasco ME, Ghobrial MW, Ross ER: Neuron-specific enolase and neurofilament protein as markers of differentiation in medulloblastoma. Surg Neurol 23: 177-182, 1985.
31. Hoshino T, Nagashima T, Murovic JA, Wilson CB, Edwards MS, Gutin PK, Davis RL and DeArmond SJ: In situ cell kinetic studies on human neuroectodermal tumors with bromodeoxyuridine labeling. J Neurosurg 64: 453-59, 1986.
32. Hoshino T, Rodriguez LA, Cho KG, Lee KS, Wilson CB, Edwards MS, Levin VA, Davis RL: Prognostic implications of the proliferative potential of low-grade astrocytomas. J Neurosurg 69: 839-842, 1988.
33. Hoshino T, Prados NI, Wdson CB, Cho KC, Lee KS, Davis RL Prognostic implications of low bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335-341, 1989.
34. Murovic JA, Nagashima T, Hoshino T, Edwards MS, Davis RL: Pediatric central nervous system tumors: a cell kinetic study with bromodeoxyuridine. Neurosurgery 19: 900-904, 1986.
35. Niedieck B, Lohler J: Expression of 3-fucosyl-N-acetyl-lactosamine on glia cells and its putative role in cell adhesion. Acta Neuropathol 75: 173-184, 1987.
36. Trojanowski J: Neurofilament proteins and human nervous system tumors. J Histochem Cytochem 35: 999-1003, 1987.
37. Schwechheimer K, Wiedenmann B, Franke WW: Synaptophysin: A reliable broad-range marker for medulloblastomas. Virchows Arch Pathol Anal 411: 53-59, 1987.
38. Fujimoto M, Weaker FJ, Herbert DC, Sharp ZD, Sheridan PJ, Story JL: Expression of three viral oncogenes (v-sis, v-myc, v-fos) in primary human brain tumors of neuroectodermal origin. Neurology 38: 289-293, 1988.
39. Zuber P, Hamou M-F, de Tribolet N: Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 22: 364-368, 1988.
40. Ng HK, Lo STH: Cytokeratin immunoreactivity in gliomas. Histopathology 14: 359-369, 1989.
41. Norimura T, Kitz K, Budka H: In situ cell kinetics in human brain tumors: A comparative immunocytochemical study of S-phase cells by a new in vitro bromodeoxyuridine labeling technique and of proliferating pool cells by monocolonal antibody Ki-67. Acta Neuropathol 77: 276-282, 1989.
42. Wiedenmann B: Synaptophysin: A widespread constituent of small neuroendocrine vesicles and a new tool in tumor diagnosis. Acta Oncol 30: 435-440, 1991.
43. Dinda AK, Kharbanda K, Sarkar C, Roy S, Mathur M, Banedi AK: In-vivo proliferative potential of primary human brain tumors - Its correlation with histological classification and morphological features. I. Gliomas. Pathology 25: 4-9, 1943.
44. Dinda AK, Kharbanda K, Sarkar C, Roy S, Mathur M, Banedi AK: In-vivo proliferative potential of primary human brain tumors - Its correlation with histological classification and morphological features. II. Nonglial Tumors. Pathology 25: 10-14, 1993.
45. Pollack IF, Camphell JW, Hamilton RL, Martinez AJ, Bozik ME: Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer 79: 849-856, 1997.
46. Zeltzer PM, Bodey B, Marlin A, Kemshead J: Immunophenotype profile of childhood medulloblastomas and supratentorial primitive neuroectodermal tumors using sixteen monoclonal antibodies. Cancer 66: 273-283, 1990.
47. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
48. Bodey B, Cosgrove M, Gonzalez-Gomez I, Siegel SE, Martin SE, Gilles FH: Co-expression of four intermediate filament subclasses in childhood glial neoplasms. Mod Pathol 4: 742-749, 1991.
49. Gianella-Borradori A, Zeltzer PM, Bodey B, Nelson M, Britton H, Marlin A: Choroid plexus tumors in childhood: Response to chemotherapy, and immunophenotypic profile using a panel of monoclonal antibodies. Cancer 69: 809-816, 1992.
50. Bodey B, Siegel SE, Peacock SJ: Expression of carcinoembryonic or related cross reacting antigens in primary pediatric neuroectodermal brain tumors. Mod Pathol 5: 432-438, 1992.
51. Bodey B, Bodey B Jr, Siegel SE. Immunophenotypic characterization of infiltrating poly- and mononuclear cells in childhood brain tumors. Mod Pathol 8: 333-338, 1995.
52. Bodey B, Siegel SE, Kaiser HE. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Anticancer Res 16: 661-674, 1996.
53. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors. Anticancer Res 17: 184-196, 1947.
54. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of pS5 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression. Anticancer Res 17: 1187-1194, 1997.
55. Bruggers CS, Tai KF, Murdock T, Sivak L, Le K, Perkins SL, Coffin CM, Carroll WL: Expression of the c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol 20: 18-25, 1998.
56. Williams BP, Abney ER, Raff MC: Macroglial cell development in embryonic rat brain: studies using monoclonal antibodies, flourescence-activated cell sorting and cell culture. Dev Biol 112: 126-134, 1985.
57. Katsura S, Suzuki J, Wada T: Statistical study of brain tumours in the neurosurgical clinics in Japan. J Neurosurg 16: 570-580, 1959.
58. von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328-338, 1995.
59. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 15: 211-221, 1995.
60. Cairncross JG: The biology of astrocytoma: lessons learned from chronic myelogenous leukemia-hypothesis. J Neuro-Oncol 5: 99-104, 1987.
61. Greaves M, Janossy G, Francis G, Minowada J: Membrane phenotypes of human leukemic cells and leukemic cell lines: Clinical correlates and biological implications. In: Differentiation of normal and neoplastic hemopoietic cells (Clarkson B, Marks PL, Till J, eds). Vol 5, pp 823-841, Cold Spring Harbor Conferences on Cell Proliferation, Cold Spring Harbor Laboratory, New York, 1977.
62. Burns BF: Molecular genetic markers in lymphoproliferative disorders. Clin Biochem 22: 33-39, 1989.
63. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
64. Bullard DE, Gillespie Y, Mahaley MS, Bigner DD: Immunobiology of human gliomas. Semin Oncol 13: 94-109, 1986.
65. Ohgaki K, Schäuble B, zur Hausen A, von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchows Arch 427: 113-118, 1995.
66. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H: Role of gemistocytes in astrocytoma progression. Lab Invest 76: 277-284, 1997.
67. Cruz-Sanchez FF, Ferreres JC, Figols J, Palacin A, Cardesa A, Rossi ML, Val-Bernal JF: Prognostic analysis of astrocytic gliomas correlating histological parameters with the proliferating cell nuclear antigen labelling index (PCNA-LI). Histol Histopathol 12: 43-49, 1997.
68. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y: Expression of tissue factor in glioma. Noshuyo Byori 13: 115-118, 1996.
69. Reyes-Mugica M, Rieger-Christ K, Ohgaki H, Ekstrand BC, Helie M. Kleinman G, Yahanda A, Fearon ER, Kleihues P, Reale MA: Loss of DCC expression and glioma progression. Cancer Res 57: 382-386, 1997.
70. Zurawel RH, Chiappa SA, Allen C, Raffel C: Sporadic medulloblastomas contain oncogenic heta-catenin mutations. Cancer Res 58: 896-899, 1998.
71. Hara A, Hirose Y, Yoshimi N, Tanaka T, Mori H: Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors. Neurol Res 19: 623-628, 1997.
72. Bodey B, Bodey B Jr, Kaiser HE: Apoptosis in the mammalian thymus during its normal histogenesis and under various in vitro and in vivo experimental conditions. In vivo 12: 123-134, 1998.
73. Müllauer L, Mosberger I, Chott A: Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod Pathol 11: 369-375, 1998.
74. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528-5530, 1995.
75. Tachibana O, Lampe J, Kleihues P, Ohgaki H: Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 92: 431-434, 1996.
76. Dietrich P-Y, Walker PR, Saas P, de Tribolet N: Immunobiology of gliomas: new perspectives for therapy. In: Challenges and opportunities in pediatric oncology (Holmes FF, Kepes JJ, Vats TS, Schuler D, Nyary I, eds). New York, Ann NY Acad Sci 824: 124-140, 1997.
77. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-L and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150: 805-814, 1997.
78. Davis EJ, Foster TD, Thomas WE: Cellular forms and functions of brain microglia. Brain Res Bull 34: 73-78, 1994.
79. Krivit W, Sung JH, Shapiro EG, Lockman L: Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 4: 385-392, 1995.
80. Walker PR, Sikorska M: New aspects of the mechanism of DNA fragmentation in apoptosis. Bichem Cell Biol 75: 287-299, 1997.
81. Walker PR, Saas P, Dietrich P-Y: Role of Fas ligand (CD95L) in immune escape: the tumor cells strikes back. J Immunol 158: 4521-4524, 1997.
82. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA: Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95-100, 1988.
83. Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-beta: biological function and chemical structure. Science 233: 532-534, 1986.
84. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiano G: Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 34: 241-251, 1992.
85. Rabbani SA: Metalloproteases and urokinase in angiogenesis and tumor progression. In vivo 12: 135-142, 1998.
86. Czubayko F, Liadet-Coopman EDE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 3: 1137-1140, 1997.
87. Rak J, Kerbel RS: bFGF and tumor angiogenesis-back in the limelight? Nature Med 3: 1083-1084, 1997.
88. Czubayko F, Smith RV, Chung HC, Wellstein A: Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chcm 269: 28243-28248, 1944.
89. Morrison RS, Giordano S, Yamaguchi F, Hendrickson S, Berger MS, Palczewski K: Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells. J Neurosci Res 34: 502-509, 1993.
90. Redekop GJ, Naus CC: Transfection of bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J Neurosurg 82: 83-90, 1995.
91. Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W, Heffner RR Jr: Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 56: 435-439, 1997.
92. Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364, 1990.
93. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J: Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67: 785-795, 1991.
94. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M: Expression and structural features of endoglin (CD105), a transforming growth factor betal and beta3 binding protein, in human melanoma. Br J Cancer 74: 1586-1591, 1996.
95. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdzar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
96. Kumar P, Wang JM, Bernabeu C: CD 105 and angiogenesis. J Pathol 178: 363-366, 1996.
97. Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M, Bernabeu C: Assignment of the human endoglin gene (END) to 9q34->qter. Cytogenet Cell Genet 64: 204-207, 1993.
98. Wang JM, Kumar S, van Agthoven A, Kumar P, Pye D, Hunter RD: Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 62: 791-796, 1995.
99. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K: Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62: 386-392, 1995.
100. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K: Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73: 213-220, 1995.
101. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 76: 187-194, 1995.
102. Zhang H, Shaw AR, Mak A, Letarte M: Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. J Immunol 156: 564-573, 1996.
103. Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD 105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 39: 239-242, 1996.
104. Shovlin CL, Scott J: Inherited diseases of the vasculature. Annu Rev Physiol 58: 483-507, 1996.
105. Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA, Letarte M: Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 58: 265-276, 1997.
106. Zulch KJ, Wechsler W: Pathology and classification of gliomas. Progr Neurol Surg, vol. 2, Karger, Basel-New York, pp 1-84, 1968.
107. Zulch KJ: Histologic classification of tumours of the central nervous system. International Histological Classification of Tumours, No. 21, World Health Organization, Geneva, 1974.
108. Zulch KJ: Principles of the new World Health Organization (WHO) classification of brain tumors. Neuroradiology 19: 54-66, 1980.
109. Szymas J: Histologic classification of central nervous system tumors by the World Health Organization. Pol J Pathol 45: 81-41, 1994.
110. Szymas J: Diagnostic immunohistochcmistry of tumors of the central nervous system. Folia Neuropathol 32: 204-214, 1994.
111. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis I: Microvessel density in brain tumors. Anticancer Res 17: 4747-4753, 1997.
112. Rojiani AM, Dorovini-Zis K: Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J Neurosurg 85: 1078-1084, 1996.
113. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
114. Shi S-R, Cote C, Kalra KL, Taylor CR, Tandon AK: A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40: 787-742, 1992.
115. Key ME, Shi S-R, Kalra KL: Antigen retrieval in formalin fixed tissues using microwave energy. US Patent # 5,244,787: 14 September 1993.
116. Beckstead JH: Improved antigen retrieval in formalin-fixed, paraffin-embedded tissues. Appl Immunohistochem 2: 274-281, 1994.
117. Cuevas EC, Bateman AC, Wilkins BS, Johnson PA, Williams JH, Lee AH, Jones DB, Wright DH: Microwave antigen retrieval in immunocytochemistry: a study of 80 antibodies. J Clin Pathol 47: 448-452, 1994.
118. Chen T, Zhang D, Shi S-R, Taylor CR: Antigen retrieval pretreatment: microwaving procedures and alternative heating methods. Biolink 4: 2, 1995.
119. Janckila AJ, Yam LT, Li C-Y: Immunoalkaline phosphatase cytochemistry. Am J Clin Pathol 84: 476-480, 1985.
120. Cattoretti G, Berti E, Schiro R, D' Amato L, Valeggio C, Rilke F: Improved avidin-biotin-peroxidase complex (ABC) staining. Histol J 20: 75-80, 1988.
121. Yam LT, Janckila AJ, Epremian BE, Li C-Y: Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemislry. Am J Clin Pathol 91: 31-36, 1989.
122. Strasburger CJ, Amir-Zaltsman Y, Kohen F: The avidin-biotin reaction as an universal amplification system in immunoassays. Prog Clin Biol Res 285: 74-100, 1988.
123. Wilchek M, Bayer EA: Introduction to avidin-biotin technology. Methods Enzymol 184: 5-13, 1940.
124. Duhamel RC, Whitehead JS: Prevention of nonspecific binding of avidin. Methods Enzymol 184: 201-207, 1990.
125. Diamandis EP, Christopoulos TK: The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625-636, 1991.
126. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
127. Battitora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
128. Battifora H, Mehta P: The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724, 1990.
129. Kleinman GM, Zagzag D, Miller DC: Diagnostic use of immunohistochemistry in neuropathology. Neurosurgery Clinics North Am 5: 97-126, 1994.
130. Jay V, Edwards V, Halliday W, Rutka J, Lau R: "Polyphenotypic" tumors in the central nervous system: problems in nosology and classification. Pediatr Pathol Lab Med 17: 369-384, 1997.
131. Beckmann MJ, Prayson RA: A clinicopathologic study of 30 cases of oligoastrocytoma including p53 immunohistochemistry. Pathology 29: 159-164, 1997.
132. Krouwer HG, van Duinen SG, Kamphorst W, van der Valk P, Algra A: Oligoastrocytomas: a clinicopathological study of 52 cases. J Neurooncol 33: 223-238, 1997.
133. Hirose T, Schneithauer BW, Lopes MB, et al: Ganglioglioma: an ultrastructural and immunohistochemical study. Cancer 79: 989-1003, 1997.
134. Taylor CR: Quality assurance and standardization in immunohistochemistry. A proposal for the annual meeting of the Biological Stain Commission, June, 1991. Biotech Histochem 67: 110-117, 1992.
135. Stemmer-Rachamimov AO, Louis DN: Histopathologic and immunohistochemical prognostic factors in malignant gliomits. Curr Opin Oncol 9: 230-234, 1997.
136. Baker DL, Molenaar WM, Trojanowski JO, Evans AE, Ross AH, Rorke LB, Packer RJ, Lee VM, Pleasure D: Nerve growth factor receptor expression in peripheral and central neuroectodermal tumors, other pediatric brain tumors, and during development of the adrenal gland. Am J Pathol 139: 115-122, 1991.
137. Kokunai T, Sawa H, Tamaki N: Functional analysis of trk proto-oncogene product in medulloblastoma cells. Neurol Med Chir 36: 796-804, 1996.
138. Pruim J, Willemsen AT, Molenaar WM, van Waarde A, Paans AM, Heesters MA, Go KG, Visser GM, Franssen EJ, Vaalburg W: Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 197: 221-226, 1995.
139. de Wolde H, Pruim J, Mastik MF, Koudstaal J, Molenaar WM:Proliferative activity in human brain tumors: comparison of histopathology and L-[1-(11)C]tyrosine PET. J Nucl Med 38: 1369-1374, 1997.
140. Sallinen P, Miettinen H, Sallinen SL, et al: Increased expression of telomerase RNA component is associated with increased cell proliferation in human astrocytomas. Am J Pathol 150: 1159-1164, 1997.
141. Kyritsis AP, Bondy ML, Hess KR, et al: Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1: 1617-1622, 1995.
142. Korshunov AG, Sycheva RV: An immunohistochemical study of the expression of the oncoprotein p53 in astrocytic gliomas of the cerebral hemispheres. Arkh Patol 58: 37-42, 1996.
143. Bhattacharjee MB, Bruner JM: p53 protein in pediatric malignant astrocytomas: a study of 21 patients. J Neurooncol 32: 225-233, 1997.
144. Ng HK, Lo SY, Huang DP, Poon WS: Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 26: 1-5, 1994.
145. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185, 1997.
146. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223, 1996.
147. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75: 1269-1278, 1997.
148. Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-Langosch K, Stavrou DK: Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. Eur J Cancer 32A: 2242-2248, 1996.
149. Asano K, Kubo O, Tajika Y, Huang MC, Takakura K, Ebina K, Suzuki S: Expression and role of cadherins in astrocytic tumors. Brain Tumor Pathol 14: 27-33, 1997.
150. Hasegawa K, Yoshida T, Matsumoto K, Katsuta K, Waga S, Sakakura T: Differential expression of tenascin-C and tenascin-X in human astrocytomas. Acta Neuropathol (Berl) 93: 431-437, 1997.
151. Herms JW, Behnke J, Bergmann M, Christen HJ, Kolb R, Wilkening M, Markakis E, Hanefeld F, Kretzschmar HA: Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 19:; 510-515, 1997.
152. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J: Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57: 3272-3280, 1997.
153. Aaronson SA: Growth factors and cancer. Science 254: 1146-1153: 1991.
154. Engebraaten O, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD: Effect of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 53: 209-214, 1993.
155. Chicoine MR, Madsen CL, Silbergeld DL: Modification of human glioma locomotion in vitro by cytokines EGF, bFGF, PDGFbb, NGF, and TNFa. Neurosurg 36: 1165-1171, 1995.
156. U HS, Espiritu OD, Kelley PY, Klauber MR, Hatton JD: The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 82: 841-846, 1995.
157. Moriuchi S, Shimizu K, Miyao Y, Hayakawa T: An immunohistoehemical analysis of medulloblastoma and PNET with emphasis on N-myc protein expression. Anticancer Res 16: 2687-2692, 1996.
158. Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, Fukui M, Tateishi J: Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 93: 225-232, 1947.
159. Chang F, Li R, Noon K, Gage D, Ladisch S: Human medulloblastoma gangliosides. Glycobiology 7: 523-530, 1997.
160. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST: Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 93: 518-527, 1997.
161. Moffett JR, Els T, Espey MG, Walter SA, Streit WJ, Namboodiri MA: Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes. Exp Neurol 144: 287-301, 1997.
162. Bodey B: Development of lymphopoiesis as a function of the thymic microenvironment. Use of CD8+ cytotoxic T lymphocytes for cellular immunotherapy of human cancer. In vivo 8: 915-943, 1994.
163. Serrador JM, Alonso-Lebrero JL, del Pozo MA, Furthmayr H, Schwartz-Albiez R, Calvo J, Lozano F, Sanchez-Madrid F: Moesin interacts with the cytoplasmic region of intercellular adhesion molecule-3 and is redistributed to the uropod of T lymphocytes during cell polarization. J Cell Biol 138: 1409-1423, 1997.
164. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995.
165. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
166. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
167. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
168. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995.
169. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, Kraft A: Angiogenesis as a target for tumor treatment. Oncology 54: 177-184, 1997.
170. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-154, 1996.
171. Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534-2539, 1996.
172. Jia WW, Tan J, Redekop GJ, Goldie JH: Toxicity studies in thymidine kinase-deficient herpes simplex virus therapy for malignant astrocytoma. J Neurosurg 85, 662-666, 1996.
173. Muir D, Johnson J, Rojiani M, Inglis BA, Rojiani A, Maria BL: Assessment of laminin-mediated glioma invasion in vitro and by glioma tumors engrafted within rat spinal cord. J Neurooncol 30: 199-211, 1996.
174. Lasner TM, Kesari S, Brown SM, Lee VM, Fraser NW, Trojanowski JO: Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 55: 1259-1269, 1996.